KNX News On DemandKNX News On Demand

FDA approves new Alzheimer's drug but what about side effects?

View descriptionShare

KNX In Depth's Charles Feldman and Rob Archer discuss a new Alzheimer's drug. The FDA has just approved a drug that might slow the pace of cognitive decline early in the disease. But it does come with risks. With us now is April Thames, Director of the UCLA Social Neuroscience and Health Psychology Lab. She's a past Alzheimer's Association Board Member.

  • Facebook
  • X (Twitter)
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. KNX News On Demand

    9,323 clip(s)

KNX News On Demand

KNX: On-Demand    
Social links
Follow podcast
Recent clips
Browse 12,608 clip(s)